Spots Global Cancer Trial Database for carcinoma, large cell
Every month we try and update this database with for carcinoma, large cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly | NCT02151149 | Non-Small Cell ... Carcinoma Squamous Cell C... Adenocarcinoma Carcinoma, Larg... Lung Neoplasm | nab-paclitaxel Carboplatin | 70 Years - | Celgene | |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | NCT00632203 | Carcinoma, Non-... Adenocarcinoma Carcinoma, Larg... Carcinoma, Squa... | Temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer | NCT00054899 | Carcinoma, Non-... Lung Neoplasm | EP2101 | 18 Years - | Epimmune | |
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly | NCT02151149 | Non-Small Cell ... Carcinoma Squamous Cell C... Adenocarcinoma Carcinoma, Larg... Lung Neoplasm | nab-paclitaxel Carboplatin | 70 Years - | Celgene | |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | NCT00632203 | Carcinoma, Non-... Adenocarcinoma Carcinoma, Larg... Carcinoma, Squa... | Temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment | NCT01497041 | Carcinoma, Non-... Carcinoma, Squa... Carcinoma, Larg... | Docetaxel Oxaliplatin | 18 Years - | Korean South West Oncology Group | |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | NCT00596830 | Carcinoma, Squa... Carcinoma, Aden... Carcinoma, Larg... Carcinoma, Non-... | CP-751,871 (Fig... Carboplatin Paclitaxel Carboplatin Paclitaxel | 18 Years - | Pfizer | |
| RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | NCT01317615 | Carcinoma, Larg... Neuroendocrine ... | RAD001 Paclitaxel Carboplatin | 18 Years - | Novartis | |
| Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer | NCT00673049 | Carcinoma, Larg... Carcinoma, Non-... Carcinoma, Squa... Carcinoma, Aden... | CP 751,871 (Fig... Erlotinib Erlotinib | 18 Years - | Pfizer | |
| Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer | NCT00673049 | Carcinoma, Larg... Carcinoma, Non-... Carcinoma, Squa... Carcinoma, Aden... | CP 751,871 (Fig... Erlotinib Erlotinib | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
